Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for each…
DRG Epidemiology's coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…
DRG Epidemiology’s coverage of major depressive disorder (MDD) (DSM-IV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MDD…
DRG Epidemiology's coverage of minor depression comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of minor depression for…
DRG Epidemiology's coverage of hypertension comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each…
The number of incident cases of AML in the European countries under study will increase by 18%, from 5,876 to 6,932, in ten years. Of the countries considered in this analysis, the incidence of…
MARKET OUTLOOKNon-alcoholic steatohepatitis (NASH) is rapidly becoming an important public health issue in the top five European markets (France, Germany, Italy, Spain, UK). High prevalence of this…
Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This…
Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected market penetration of the fourth anti-CGRP-…
DRG Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech…
MARKET OUTLOOK Type 2 diabetes (T2D) has an extremely high prevalence in the top five European markets (France, Germany, Italy, Spain, UK). Low-cost metformin (Merck KgaA’s Glucophage, generics)…
DRG Epidemiology's coverage of Parkinson's disease (PD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen),…
MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…
